Abstract
Metabolic liver diseases (MLD) are an important group of disorders presenting with neonatal cholestasis (NC). The spectrum of liver involvement is wide and the presumptive diagnosis is traditionally based on clinical and laboratory findings. Recently, next-generation sequencing (NGS) panels have emerged as an appealing tool to diagnose neonatal/infantile cholestatic disorders. The aim of this study was to identify clinical phenotypes of liver injury and contribute to find a diagnostic methodology that integrates new molecular diagnostic tools. We retrospectively analyzed the clinical and biochemical features of 16 patients with MLD and NC. Patients were categorized into three groups: A—NC with liver failure (N = 8): tyrosinemia type I (n = 2), classic galactosemia (n = 5), mitochondrial DNA depletion syndrome (n = 1); B—NC evolving with chronic liver disease (N = 5): argininemia (n = 2); mitochondrial cytopathy (n = 1); congenital disorders of glycosylation type Ia (n = 1); Zellweger syndrome (n = 1); and C—transient NC (N = 3): Niemann-Pick type C (n = 2), citrullinemia type II (n = 1).
Conclusion: MLD presenting with NC can be categorized into three main clinical phenotypes of liver injury. We highlight transient NC as a clue for MLD that must be pursued. New molecular diagnostic tools can play a key role, but application criteria must be established to make them cost-effective.
What is Known: • Metabolic liver diseases are an important group of disorders presenting with neonatal cholestasis. • The diagnostic approach is challenging and traditionally based on clinical and laboratory findings. Next-generation sequencing is a recent and rapidly developing tool in pediatric hepatology. | |
What is New: • We provide a liver-targeted characterization of metabolic liver diseases presenting with neonatal cholestasis, categorizing them into three clinical phenotypes that may narrow the diagnostic possibilities. • A clinical decision-making algorithm is proposed, in which the NGS technology is integrated. |
Similar content being viewed by others
Abbreviations
- cB:
-
Conjugated bilirubin
- CDG:
-
Congenital disorder of glycosylation
- GGT:
-
Gamma-glutamyltransferase
- HE:
-
Hepatic encephalopathy
- IEM:
-
Inborn errors of metabolism
- INR:
-
International normalized ratio
- LF:
-
Liver failure
- MLD:
-
Metabolic liver diseases
- NBS:
-
Newborn screening
- NC:
-
Neonatal cholestasis
- NGS:
-
Next-generation sequencing
- NP-C:
-
Niemann-Pick type C
- OLT:
-
Orthotopic liver transplant
- PFIC:
-
Progressive familiar intrahepatic cholestasis
References
Balistreri WF (1985) Neonatal cholestasis. J Pediatr 106(2):171–184
Behjati S, Tarpey PS (2013) What is next generation sequencing? Arch Dis Child Educ Pract Ed 98(6):236–238
Bodamer OA, Hoffmann GF, Lindner M (2007) Expanded newborn screening in Europe 2007. J Inherit Metab Dis 30:439–444
Bosch AM (2006) Classical galactosemia revisited. J Inherit Metab Dis 29:516–525
Braga AC, Vilarinho L, Ferreira E, Rocha H (1997) Hyperargininemia presenting as persistent neonatal jaundice and hepatic cirrhosis. J Pediatr Gastroenterol Nutr 24(2):218–221
Burton BK, Balwani M, Feillet F et al (2015) A phase 3 trial of sebelipase alfa in lysosomal acid lipase deficiency. N Engl J Med 373(11):1010–1020
Champion V, Carbajal R, Lozar J, Girard I, Mitanchez D (2012) Risk factors for developing transient neonatal cholestasis. J Pediatr Gastroenterol Nutr 55(5):592–598
Clayton PT (2011) Disorders of bile acid synthesis. J Inherit Metab Dis 34(3):593–604
Coene KLM, Kluijtmans LAJ, van der Heeft E, Engelke UFH, de Boer S, Hoegen B, Kwast HJT, van de Vorst M, Huigen MCDG, Keularts IMLW, Schreuder MF, van Karnebeek CDM, Wortmann SB, de Vries MC, Janssen MCH, Gilissen C, Engel J, Wevers RA (2018) Next-generation metabolic screening: targeted and untargeted metabolomics for the diagnosis of inborn errors of metabolism in individual patients. J Inherit Metab Dis 41(3):337–353
Damen G, de Klerk H, Huijmans J, den Hollander J, Sinaasappel M (2004) Gastrointestinal and other clinical manifestations in 17 children with congenital disorders of glycosylation type Ia, Ib, and Ic. J Pediatr Gastroenterol Nutr 38(3):282–287
Fawaz R, Baumann U, Ekong U, Fischler B, Hadzic N, Mack CL, McLin VA, Molleston JP, Neimark E, Ng VL, Karpen SJ (2017) Guideline for the evaluation of cholestatic jaundice in infants: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr 64:154–168
Fellman V, Kotarsky H (2011) Mitochondrial hepatopathies in the newborn period. Semin Fetal Neonatal Med 16(4):222–228
Ghosh A, Schlecht H, Heptinstall LE (2017) Diagnosing childhood-onset inborn errors of metabolism by next-generation sequencing. Arch Dis Child 102(11):1019–1029
Gomes Martins E, Santos Silva E, Vilarinho S, Saudubray JM, Vilarinho L (2010) Neonatal cholestasis: an uncommon presentation of hyperargininemia. J Inherit Metab Dis 33(Suppl 3):S503–S506
Herbst SM, Schirmer S, Posovszky C, Jochum F, Rödl T, Schroeder JA, Barth TF, Hehr U, Melter M, Vermehren J (2015) Taking the next step forward - diagnosing inherited infantile cholestatic disorders with next generation sequencing. Mol Cell Probes 29(5):291–298
Kuhlenbäumer G, Hullmann J, Appenzeller S (2011) Novel genomic techniques open new avenues in the analysis of monogenic disorders. Hum Mutat 32:144–151
Mancuso M, Ferraris S, Pancrudo J, Feigenbaum A, Raiman J, Christodoulou J, Thorburn DR, DiMauro S (2005) New DGK gene mutations in the hepatocerebral form of mitochondrial DNA depletion syndrome. Arch Neurol 62:745–747
Mandel H, Szargel R, Labay V, Elpeleg O, Saada A, Shalata A, Anbinder Y, Berkowitz D, Hartman C, Barak M, Eriksson S, Cohen N (2001) The deoxyguanosine kinase gene is mutated in individuals with depleted hepatocerebral mitochondrial DNA. Nature Genet 29:337–341
Marques-da-Silva D, dos Reis Ferreira V, Monticelli M, Janeiro P, Videira PA, Witters P, Jaeken J, Cassiman D (2017) Liver involvement in congenital disorders of glycosylation (CDG): a systematic review of the literature. J Inherit Metab Dis 40:195–207
Matthijs G, Schollen E, Pardon E, Veiga-Da-Cunha M, Jaeken J, Cassiman JJ, Van Schaftingen E (1997) Mutations in PMM2, a phosphomannomutase gene on chromosome 16p13, in carbohydrate-deficient glycoprotein type I syndrome (Jaeken syndrome). Nature Genet 16:88–92
Mayorandan S, Meyer U, Gokcay G, Segarra NG, de Baulny HO, van Spronsen F, Zeman J, de Laet C, Spiekerkoetter U, Thimm E, Maiorana A, Dionisi-Vici C, Moeslinger D, Brunner-Krainz M, Lotz-Havla AS, Cocho de Juan JA, Couce Pico ML, Santer R, Scholl-Bürgi S, Mandel H, Bliksrud YT, Freisinger P, Aldamiz-Echevarria LJ, Hochuli M, Gautschi M, Endig J, Jordan J, McKiernan P, Ernst S, Morlot S, Vogel A, Sander J, Das AM (2014) Cross-sectional study of 168 patients with hepatorenal tyrosinaemia and implications for clinical practice. Orphanet J Rare Dis 9(1):107
McKiernan PJ (2002) Neonatal cholestasis. SeminNeonatol 7(2):153–165
Mengel E, Klünemann HH, Lourenço CM, Hendriksz CJ, Sedel F, Walterfang M, Kolb SA (2013) Niemann-Pick disease type C symptomatology: an expert-based clinical description. Orphanet J Rare Dis 8:166
Moyer V, Freese DK, Whitington PF, Olson AD, Brewer F, Colletti RB, Heyman MB (2004) Guideline for the evaluation of cholestatic jaundice in infants: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 39(2):115–128
Nicastro E, D’Antiga L (2018) Next generation sequencing in pediatric hepatology and liver transplantation. Liver Transpl 24(2):282–293
Santos Silva E, Moreira Silva H, Azevedo Lijnzaat L, Melo C, Costa E, Martins E, Lopes AI (2017) Clinical practices among healthcare professionals concerning neonatal jaundice and pale stools. Eur J Pediatr 176(3):361–369
Santos Silva E, Klaudel-Dreszler M, Bakuła A, Oliva T, Sousa T, Fernandes PC, Tylki-Szymańska A, Kamenets E, Martins E, Socha P (2018) Early onset lysosomal acid lipase deficiency presenting as secondary hemophagocytic lymphohistiocytosis: two infants treated with sebelipase alfa. Clin Res Hepatol Gastrenterol 42(5):e77–e82
Schukfeh N, Metzelder ML, Petersen C, Reismann M, Pfister ED, Ure BM, Kuebler JF (2012) Normalization of serum bile acids after partial external biliary diversion indicates an excellent long-term outcome in children with progressive familial intrahepatic cholestasis. J Pediatr Surg 47(3):501–505
Silva ES, Cardoso ML, Vilarinho L, Medina M, Barbot C, Martins E (2013) Liver transplantation prevents progressive neurological impairment in argininemia. JIMD Rep 11:25–30
Squires RH, Shneider BL, Bucuvalas J, Alonso E, Sokol RJ, Narkewicz MR, Dhawan A, Rosenthal P, Rodriguez-Baez N, Murray KF, Horslen S, Martin MG, Lopez MJ, Soriano H, McGuire BM, Jonas MM, Yazigi N, Shepherd RW, Schwarz K, Lobritto S, Thomas DW, Lavine JE, Karpen S, Ng V, Kelly D, Simonds N, Hynan LS (2006) Acute liver failure in children: the first 348 patients in the pediatric acute liver failure study group. J Pediatr 148(5):652–658
Togawa T, Sugiura T, Ito K, Endo T, Aoyama K, Ohashi K, Negishi Y, Kudo T, Ito R, Kikuchi A, Arai-Ichinoi N, Kure S, Saitoh S (2016) Molecular genetic dissection and neonatal/infantile intrahepatic cholestasis using targeted next-generation sequencing. J Pediatr 171:171–7.e1–4
Vilarinho L, Rocha H, Sousa C, Marcão A, Fonseca H, Bogas M, Osório RV (2010) Four years of expanded newborn screening in Portugal with tandem mass spectrometry. J Inherit Metab Dis 33(Suppl 3):S133–S138
Yerushalmi B, Sokol RJ, Narkewicz MR, Smith D, Ashmead JW, Wenger DA (2002) Niemann-Pick disease type C in neonatal cholestasis at a North American center. J Pediatr Gastroenterol Nutr 35(1):44–50
Yubero D, Brandi N, Ormazabal A, Garcia-Cazorla À, Pérez-Dueñas B, Campistol J, Ribes A, Palau F, Artuch R, Armstrong J (2016) Targeted next generation sequencing in patients with inborn errors of metabolism. PLoS One 11(5):e0156359
Author information
Authors and Affiliations
Contributions
Helena Moreira Silva: study concept and design; acquisition of data; analysis and interpretation of data; drafting of the manuscript.
Inês Maio: acquisition of data, analysis and interpretation of data.
Anabela Bandeira and Esmeralda Martins: patient diagnosis and follow-up, analysis and interpretation of data; critical revision of the manuscript.
Ermelinda Santos Silva: patient diagnosis and follow-up, study concept and design; study supervision; critical revision of the manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
The study was approved by our institutional scientific and ethics committee [Study N/REF.ª 2016. 081 (069-DEFI/066-CES)].
Clinical trial registration
Not applicable.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Additional information
Communicated by Peter de Winter
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Moreira-Silva, H., Maio, I., Bandeira, A. et al. Metabolic liver diseases presenting with neonatal cholestasis: at the crossroad between old and new paradigms. Eur J Pediatr 178, 515–523 (2019). https://doi.org/10.1007/s00431-019-03328-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00431-019-03328-5